Peptide LibraryPTH(1-34) Analog (Generic Teriparatide) dosage in published studies and labels
These are the doses used for PTH(1-34) Analog (Generic Teriparatide) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
PTH(1-34) has an FDA-approved human dosage only as teriparatide, 20 mcg once daily by subcutaneous injection for osteoporosis at high risk for fracture; Forteo and teriparatide labels from other companies give the same dose. This profile covers generic, compounded and research PTH(1-34) preparations, and research or compounded vials are not FDA-approved and are not the labelled products. No label covers fracture or injury healing.
FDA Approved
| Human dosing established | Yes |
|---|---|
| Studied dose range | 20 mcg once daily (approved teriparatide products) |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | Up to 2 years in a lifetime as a rule; longer only if fracture risk remains or returns to high (teriparatide labels) |
| Half-life | About 1 hour after subcutaneous injection (Forteo label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Teriparatide Injection (Teva), osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | Treatment of osteoporosis | Teriparatide Injection (Teva) — FDA prescribing information, DailyMed |
| FDA label — Teriparatide Injection (Alvogen), osteoporosisFDA-approved label · FDA prescribing information | The same three osteoporosis populations | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | Treatment of osteoporosis | Teriparatide Injection (Alvogen) — FDA prescribing information, DailyMed |
| FDA label — Forteo, osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk | 20 mcg | Subcutaneous, thigh or abdomen; not intravenous or intramuscular | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | In the label's postmenopausal study (1637 women), new vertebral fractures occurred in 5.0% with 20 mcg daily against 14.3% with placebo | FORTEO (teriparatide injection) — FDA prescribing information, DailyMed |
| Distal radius fracture healing — randomised trial of teriparatide (Aspenberg et al., 2010)Clinical trial · Randomised double-blind placebo-controlled trial | Postmenopausal women aged 45 to 85 with a distal radial fracture treated by closed reduction without surgery (n=102) | 20 mcg or 40 mcg, against placebo | Injection; route not stated in the indexed abstract | Once daily, started within 10 days of the fracture | 8 weeks | The primary hypothesis, that 40 mcg would shorten the time to cortical bridging, was not supported; in post hoc analysis healing was faster with 20 mcg than placebo (median 7.4 vs 9.1 weeks), which the authors say should be interpreted with caution | Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. |
Where sources disagree
- Teriparatide has the same sequence as the first 34 amino acids of human parathyroid hormone; the labels describe Forteo and Alvogen's product as recombinant and Teva's as chemically synthesised. The FDA-approved products (Forteo and the Teva, Alvogen and other teriparatide injections on DailyMed) are prefilled pens of 560 mcg in 2.24 mL that deliver 28 daily doses of 20 mcg. A PTH(1-34) powder vial sold for research or made by a compounder is not one of these products: its identity, content and sterility are not covered by the labels, and the labels' regimens do not describe it.
- DailyMed also lists teriparatide acetate as a bulk powder from an ingredient supplier. That listing is a raw material, not a finished medicine with a dosage.
- The teriparatide labels list osteosarcoma under Warnings and Precautions (seen in rats; reported in patients after marketing, without an increased risk in human observational studies) and say to avoid it in people at higher baseline risk, such as those with open growth plates, Paget's disease, bone metastases or prior skeletal radiation. They also warn about hypercalcaemia and orthostatic hypotension.
- Bone or injury healing is not an approved use. In the randomised fracture trial cited here, 40 mcg daily did not significantly shorten healing against placebo and only a post hoc comparison favoured 20 mcg. See the teriparatide profile for the approved product, and abaloparatide for the related PTHrP analogue, which is a different molecule with its own label.